Research programme: cardiovascular disease - Millennium Pharmaceuticals
Alternative Names: Cardiovascular disease research programme - Millennium PharmaceuticalsLatest Information Update: 29 Jun 2006
At a glance
- Originator Millennium Pharmaceuticals
- Class
- Mechanism of Action Angiotensin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 21 Mar 2001 New profile
- 21 Mar 2001 Preclinical development for Congestive heart failure in USA (Unknown route)
- 21 Mar 2001 Preclinical development for Hypertension in USA (Unknown route)